Liver health may change how drug KP-001 works in the body

NCT ID NCT06619054

Completed Knowledge-focused Sponsor: Kaken Pharmaceutical Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 study tested a single 50 mg dose of the drug KP-001 in 24 adults, some with healthy livers and others with different levels of liver impairment. The goal was to see how liver function affects the drug's levels and safety in the body. Results could help guide future dosing for patients with liver disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KP-001
What this could lead to: If successful, this study could help doctors decide the right dose of KP-001 for people with liver problems.
What could go wrong: This is a very early, small study in 24 people. It only looks at how the body processes the drug, not whether it works for any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY ADULTS HEPATIC IMPAIRMENT

Contacts and locations

Show contact details

Locations

Sites contracted by Parexel

San Antonio, Texas, 08103, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.